How Much Does Evenity (Romosozumab) Cost in Alaska in 2026?

Alaska Retail Pricing for Evenity in 2026

The average cash-pay price for Evenity at Alaska retail pharmacies in 2026 is $1,825 per monthly dose, matching the Amgen/UCB wholesale acquisition cost (WAC). This price applies to the standard 210 mg prefilled syringe kit, which contains two 105 mg/1.17 mL syringes administered as a single subcutaneous dose.

Alaska's geographic isolation contributes to limited pharmacy competition for specialty biologics. Unlike states with dozens of competing specialty pharmacies within a single metro area, many Alaskan communities rely on one or two pharmacies capable of handling cold-chain biologics like romosozumab. The drug requires refrigerated storage at 2°C to 8°C per the FDA-approved prescribing information, and shipping it to remote Alaskan locations adds logistical cost that pharmacies rarely absorb.

Over a full 12-dose treatment course, patients paying out of pocket face a total expense near $21,900. That figure assumes no price increases during the treatment year. Romosozumab is prescribed as a time-limited course (not indefinite therapy), which at least caps total spending compared to ongoing treatments like denosumab, where costs accumulate year after year.

Patients in Anchorage, Fairbanks, or Juneau may find marginally different pricing at competing pharmacies, but the WAC floor of $1,825 means savings through retail price-shopping alone are minimal.

Alaska Medicaid Does Not Cover Evenity

Alaska Medicaid does not cover Evenity (romosozumab) for severe osteoporosis as of 2026. This is a significant barrier for low-income Alaskans with high fracture risk, since Medicaid is the primary insurer for roughly 1 in 4 Alaska residents.

State Medicaid formularies make independent coverage decisions for specialty biologics. Alaska's decision not to include romosozumab likely reflects cost-containment priorities: at $21,900 per treatment course, the per-patient outlay is substantial. By contrast, generic alendronate (a bisphosphonate) costs under $15 per month, and even branded denosumab (Prolia) carries a lower per-injection price point.

For Medicaid enrollees, practical alternatives include:

• Bisphosphonates (alendronate, risedronate, zoledronic acid), which are first-line therapies covered by Alaska Medicaid and supported by decades of fracture-reduction data from trials like FIT
• Denosumab (Prolia), a RANK ligand inhibitor administered every six months, which carries broader Medicaid coverage in most states
• Teriparatide (Forteo) or abaloparatide (Tymlos), parathyroid hormone analogues that may have coverage through Medicaid prior authorization pathways

If a treating physician believes romosozumab is medically necessary and no alternative is appropriate, a formal exception request can be submitted to Alaska Medicaid. These requests require documentation of prior treatment failures or contraindications to formulary alternatives. Approval is not guaranteed. A 2023 Endocrine Society guideline update supports anabolic-first treatment sequencing in patients at very high fracture risk, which may strengthen the clinical rationale in an exception request.

Commercial Insurance Coverage in Alaska

Most major commercial insurers operating in Alaska, including Premera Blue Cross Blue Shield of Alaska, Moda Health, and Aetna, may cover Evenity after prior authorization. Coverage is not automatic. Plans typically require documentation that the patient meets specific criteria.

Common prior authorization requirements for romosozumab include:

1. A confirmed diagnosis of osteoporosis (T-score of <-2.5 at the hip or spine on DXA)
2. High fracture risk as defined by FRAX score or history of fragility fracture
3. Failure of, intolerance to, or contraindication to at least one first-line agent (usually a bisphosphonate)
4. Prescribing by or in consultation with an endocrinologist or rheumatologist

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared to alendronate alone at 24 months (Saag et al., NEJM 2017). This data point is often cited in prior authorization appeals to justify romosozumab over bisphosphonate monotherapy in very high-risk patients.

Even with approval, cost-sharing varies. Some plans classify Evenity under specialty pharmacy tiers with coinsurance of 20% to 40%, meaning the patient's share could range from $365 to $730 per injection before any manufacturer assistance. Plans with annual out-of-pocket maximums will cap total patient spending, but those limits may be $8,000 to $12,000 for specialty tiers.

Patients should request a benefits investigation through their insurer or through Amgen's support line before starting treatment. Knowing the tier, copay, and annual cap in advance prevents surprise bills mid-course.

How the Amgen/UCB Savings Card Works in Alaska

Amgen offers the Evenity Copay Card program for commercially insured patients. This is one of the most effective tools for reducing out-of-pocket costs in Alaska. The card is accepted at specialty pharmacies statewide.

Key details of the program:

• Eligibility: patients with commercial (private) insurance only. Medicare, Medicaid, Tricare, and other government-funded plans are excluded.
• Savings: eligible patients may pay as little as $5 per monthly dose, with Amgen covering the remainder of the copay up to a program maximum.
• Annual cap: the program has a maximum annual benefit (typically around $12,000 to $15,000, though terms change annually). For a 12-month course at $1,825/month, this cap is often sufficient to cover the full copay difference.
• Enrollment: patients can enroll online, by phone, or through their prescribing provider's office.

The savings card does not reduce the drug's list price. It offsets the patient's cost-sharing obligation. This means the insurer still processes the claim at full price, and the card pays whatever the plan leaves as the patient's responsibility (copay or coinsurance).

One limitation applies specifically to Alaska: patients using mail-order specialty pharmacies based outside the state should confirm the card is accepted by their specific pharmacy benefit manager (PBM). Most national PBMs (Express Scripts, CVS Caremark, OptumRx) process the card without issues, but verification avoids delays in a time-sensitive 12-month treatment window.

For patients whose commercial plan denies coverage entirely, the copay card does not apply because there is no insurance claim to supplement. In that scenario, Amgen's separate patient assistance program (Amgen Safety Net Foundation) may provide the drug at no cost to qualifying patients based on income.

Compounded Romosozumab Through 503A Pharmacies

Compounded romosozumab is available in Alaska through licensed 503A compounding pharmacies. This is legal under federal law (section 503A of the Federal Food, Drug, and Cosmetic Act) when a pharmacist prepares the compound based on a valid patient-specific prescription.

A few critical distinctions separate compounded romosozumab from the branded Evenity product:

• No FDA approval: compounded versions have not undergone the clinical trial process that established Evenity's efficacy and safety profile in the ARCH and FRAME trials
• No standardized formulation: potency, sterility, and bioavailability may vary between compounding pharmacies
• No manufacturer support: no copay card, no patient assistance program, and no adverse event reporting infrastructure
• Prescriber liability shifts: the prescribing clinician assumes greater medicolegal responsibility when ordering a compounded biologic

The FDA has raised concerns about compounded biologics generally, noting that complex proteins like monoclonal antibodies and sclerostin inhibitors are difficult to replicate outside controlled manufacturing environments. Romosozumab is a humanized monoclonal antibody with specific glycosylation and folding requirements that affect its pharmacologic activity.

Pricing for compounded romosozumab through 503A pharmacies varies, but it is typically offered at a fraction of the branded price. Some reports cite costs near zero through certain promotional arrangements, though patients should scrutinize what that pricing actually reflects. A compounded biologic priced dramatically below the branded version warrants questions about sourcing, testing, and quality assurance.

For Alaska patients considering this route, the Alaska Board of Pharmacy regulates 503A pharmacies operating within the state. Patients can verify a pharmacy's license status through the board's online portal.

Telehealth Prescribing of Evenity in Alaska

Alaska permits telehealth prescribing of Evenity (romosozumab). This is particularly relevant given the state's vast geography: Alaska spans 663,300 square miles, and many residents live hours from the nearest endocrinologist or rheumatologist.

A telehealth consultation can accomplish several steps in the prescribing pathway:

• Review of DXA scan results and fracture history
• Assessment of cardiovascular risk (romosozumab carries a boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death based on ARCH trial findings)
• Discussion of treatment alternatives and sequencing
• Initiation of prior authorization paperwork

The injection itself requires in-person administration. Romosozumab is delivered as two consecutive subcutaneous injections (each 105 mg/1.17 mL) in the abdomen, thigh, or upper arm, administered by a healthcare provider. Patients do not self-inject. This means even telehealth-initiated prescriptions require a local clinic, infusion center, or visiting nurse for monthly administration.

For patients in rural Alaska, the Indian Health Service (IHS) and tribal health organizations (such as the Alaska Native Tribal Health Consortium) may support both the telehealth consultation and local injection administration. These organizations sometimes have separate formulary access through the Federal Supply Schedule, where drug pricing differs from commercial and Medicaid rates.

Comparing Evenity to Other Osteoporosis Treatments in Alaska

Cost alone does not determine the right osteoporosis treatment. But for Alaska patients facing a $21,900 out-of-pocket course with no Medicaid backstop, understanding the price-to-benefit ratio of alternatives is practical.

| Treatment | Monthly Cost (approx.) | Route | Duration | Key Trial Evidence | |---|---|---|---|---| | Alendronate (generic) | $10-15 | Oral, weekly | 3-5+ years | FIT: 47% vertebral fracture reduction | | Zoledronic acid (Reclast) | $100-200 (annual IV) | IV, yearly | 3-6 years | HORIZON: 70% vertebral fracture reduction | | Denosumab (Prolia) | $900-1,100 | SC, every 6 months | Indefinite | FREEDOM: 68% vertebral fracture reduction | | Teriparatide (Forteo) | $1,200-1,500 | SC, daily | 24 months | Fracture Prevention Trial | | Romosozumab (Evenity) | $1,825 | SC, monthly | 12 months | ARCH: 48% vertebral fracture reduction vs. alendronate |

The AACE/ACE 2020 guidelines recommend anabolic therapy (romosozumab, teriparatide, or abaloparatide) as first-line treatment for patients at very high fracture risk, defined as a recent fracture within 24 months, T-score below -3.0, or multiple vertebral fractures. For these patients, starting with a bone-forming agent followed by an antiresorptive (like a bisphosphonate or denosumab) produces better long-term outcomes than antiresorptive therapy alone (Camacho et al., Endocrine Practice 2020).

The cardiovascular safety signal in romosozumab deserves attention. In the ARCH trial, cardiovascular serious adverse events occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group over 12 months. The FDA's boxed warning states that romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year.

Practical Steps to Reduce Your Evenity Cost in Alaska

For Alaska patients prescribed romosozumab, a specific sequence of actions can minimize financial exposure:

1. Request a benefits investigation through your insurer before filling the prescription. Ask for the tier, copay, coinsurance rate, and annual out-of-pocket maximum.
2. Apply for the Amgen Evenity Copay Card if commercially insured. Enrollment takes minutes and can reduce monthly copays to $5.
3. If uninsured or underinsured, contact the Amgen Safety Net Foundation at 1-888-762-6436 to determine eligibility for free drug through their patient assistance program.
4. If on Alaska Medicaid, work with your prescriber to submit a formulary exception request citing the Endocrine Society and AACE guidelines, your specific fracture risk profile, and documentation of prior treatment failures.
5. Explore 503A compounding only after discussing risks and limitations with your prescribing physician. Verify the pharmacy's Alaska Board of Pharmacy license independently.
6. Use telehealth for the initial consultation and ongoing monitoring if travel to a specialist is prohibitive. Arrange local injection administration through your primary care clinic or tribal health facility.

The 12-month treatment window for romosozumab means delays in resolving insurance or cost issues can directly reduce treatment effectiveness. Starting the authorization process before the first injection date avoids gaps in the monthly dosing schedule.